Company Description
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States.
The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis.
Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma.
The company also develops TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning; TLX300 for the treatment of soft tissue sarcoma; and TLX592, a prostate cancer therapy candidate for targeted alpha therapy.
Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.
| Country | Australia |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 415 |
| CEO | Christian Behrenbruch |
Contact Details
Address: 55 Flemington Road, Suite 401 North Melbourne, VIC 3051 Australia | |
| Phone | 61 3 9093 3855 |
| Website | telixpharma.com |
Stock Details
| Ticker Symbol | TLX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | AUD |
| CIK Code | 0002007191 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Richard Valeix M.B.A. | Chief Executive Officer of Telix Therapeutics |
| Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBA | Co-Founder, MD, Group Chief Executive Officer and Executive Director |
| Darren Smith B.Bus., FCPA, M.B.A. | Group Chief Financial Officer |
| Dr. Andreas Kluge M.D., Ph.D. | Chief Medical Advisor |
| Dr. David N. Cade M.B.A., M.D., MBBS | Group Chief Medical Officer |
| Darren Patti | Group Chief Operating Officer |
| Dr. Michael Wheatcroft B.Sc., BSc(Hons), Ph.D., Ph.D., (Cantab) | Chief Scientist |
| Craig Ulrick | Chief Information Officer |
| Kyahn Williamson B.A. | Senior Vice President of Corporate Communications and Investor Relations |
| Lena Moran-Adams L.L.B. | Group General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 19, 2024 | 6-K | Report of foreign issuer |
| Nov 14, 2024 | 6-K | Report of foreign issuer |
| Nov 12, 2024 | EFFECT | Notice of Effectiveness |
| Nov 12, 2024 | CERT | Certification by an exchange approving securities for listing |
| Oct 30, 2024 | 20FR12B/A | Filing |
| Oct 17, 2024 | F-6 | Filing |
| Oct 17, 2024 | 20FR12B | Filing |
| Sep 13, 2024 | DRS | [Cover] Draft Registration Statement |
| Jun 14, 2024 | RW | Filing |
| Jun 14, 2024 | RW | Filing |